These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 27586014)
41. [Long-Term Survival after Locally Advanced Pancreatic Ductal Adenocarcinoma Treated with Multidisciplinary Therapy - A Case Report]. Ueno G; Yamada D; Eguchi H; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Mori M; Doki Y Gan To Kagaku Ryoho; 2016 Nov; 43(12):1668-1670. PubMed ID: 28133093 [TBL] [Abstract][Full Text] [Related]
42. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Tomimaru Y; Eguchi H; Satoh T; Tomokuni A; Asaoka T; Wada H; Marubashi S; Ogawa K; Takehara T; Mori M; Doki Y; Nagano H Jpn J Clin Oncol; 2015 Apr; 45(4):343-8. PubMed ID: 25589454 [TBL] [Abstract][Full Text] [Related]
43. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy. Hashimoto D; Satoi S; Yamamoto T; Yamaki S; Ishida M; Ryota H; Sakaguchi T; Hirooka S; Inoue K; Sekimoto M Surg Today; 2021 Nov; 51(11):1872-1876. PubMed ID: 34086127 [TBL] [Abstract][Full Text] [Related]
44. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. Shintakuya R; Kondo N; Murakami Y; Uemura K; Nakagawa N; Okano K; Takahashi S; Sueda T Pancreatology; 2018 Mar; 18(2):191-197. PubMed ID: 29295776 [TBL] [Abstract][Full Text] [Related]
45. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Yoshitomi H; Togawa A; Kimura F; Ito H; Shimizu H; Yoshidome H; Otsuka M; Kato A; Nozawa S; Furukawa K; Miyazaki M; Cancer; 2008 Nov; 113(9):2448-56. PubMed ID: 18823024 [TBL] [Abstract][Full Text] [Related]
46. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Cloyd JM; Wang H; Egger ME; Tzeng CD; Prakash LR; Maitra A; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Overman MJ; Koay EJ; Das P; Herman JM; Kim MP; Vauthey JN; Aloia TA; Fleming JB; Lee JE; Katz MHG JAMA Surg; 2017 Nov; 152(11):1048-1056. PubMed ID: 28700784 [TBL] [Abstract][Full Text] [Related]
47. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy]. Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370 [TBL] [Abstract][Full Text] [Related]
48. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543 [TBL] [Abstract][Full Text] [Related]
49. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370 [TBL] [Abstract][Full Text] [Related]
50. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991 [TBL] [Abstract][Full Text] [Related]
51. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakagawa N; Ohge H; Sueda T Am J Surg; 2008 Jun; 195(6):757-62. PubMed ID: 18367131 [TBL] [Abstract][Full Text] [Related]
52. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005 [TBL] [Abstract][Full Text] [Related]
53. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study. Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030 [TBL] [Abstract][Full Text] [Related]
54. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience. Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637 [TBL] [Abstract][Full Text] [Related]
55. Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer. Takahashi H; Akita H; Ioka T; Wada H; Tomokoni A; Asukai K; Ohue M; Yano M; Ishikawa O Pancreas; 2018 Oct; 47(9):1135-1141. PubMed ID: 30134354 [TBL] [Abstract][Full Text] [Related]
56. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. Satoi S; Toyokawa H; Yanagimoto H; Yamamoto T; Kamata M; Ohe C; Sakaida N; Uemura Y; Kitade H; Tanigawa N; Inoue K; Matsui Y; Kwon AH J Gastrointest Surg; 2012 Apr; 16(4):784-92. PubMed ID: 22160780 [TBL] [Abstract][Full Text] [Related]
57. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy. Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066 [TBL] [Abstract][Full Text] [Related]
58. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715 [TBL] [Abstract][Full Text] [Related]
59. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Liu Z; Luo G; Guo M; Jin K; Xiao Z; Liu L; Liu C; Xu J; Ni Q; Long J; Yu X Pancreatology; 2015; 15(3):253-8. PubMed ID: 25921232 [TBL] [Abstract][Full Text] [Related]
60. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Miyakita H; Ogimi T; Nagase H Cancer Chemother Pharmacol; 2017 Jun; 79(6):1077-1085. PubMed ID: 28417167 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]